Collapse all
The Business Model Canvas reveals a high-value, specialized B2B service that leverages a specific biological discovery to solve a critical bottleneck in neuropsychiatric drug development. The model shifts the risk from the drug developer to the assay provider, creating a high-margin 'filter' service for pharmaceutical pipelines.
3 Academic Neuropharmacology Labs Partnerships with researchers who discovered the intracellular 5-HT2AR bias to refine assay sensitivity and validation protocols. Specialized Reagent Suppliers Suppliers of high-affinity monoclonal antibodies and fluorescent markers capable of distinguishing surface from cytoplasmic receptor pools. CRO Strategic Alliances Partnerships with large-scale CROs like Eurofins to integrate this niche assay into their broader pharmacological screening suites. 3 Assay Validation & Standardization Developing a reproducible protocol that consistently differentiates between surface-mediated and intracellular-mediated signaling. High-Throughput Screening (HTS) Executing large-scale compound library tests for pharmaceutical clients to identify location-biased agonists. Data Interpretation & Reporting Translating raw signaling data into a 'location-bias score' that predicts the likelihood of non-hallucinogenic neuroplasticity. 3 Proprietary Assay Protocol The specific methodology for isolating and measuring intracellular 5-HT2AR activation without surface interference. Specialized Cell Lines Engineered cell models that accurately mimic the subcellular distribution of 5-HT2A receptors found in the CNS. Pharmacological Expertise PhD-level scientists specializing in G-protein coupled receptor (GPCR) signaling and subcellular trafficking. 3 Hallucination Risk Mitigation Provides a high-probability filter to remove compounds that trigger surface-receptor-mediated hallucinations before expensive in vivo trials. Targeted Neuroplasticity Screening Enables the discovery of 'non-hallucinogenic antidepressants' by isolating compounds that specifically activate the intracellular receptor pool. Reduced R&D Cycle Time Accelerates the lead optimization phase by providing precise spatial-bias data early in the drug discovery funnel. 2 Technical Consultancy Deep collaboration with client medicinal chemists to iterate on compound structures based on the assay's bias results. Service Level Agreements (SLAs) Strict contractual guarantees on data precision, turnaround time, and confidentiality for proprietary compound libraries. 3 Direct B2B Sales Direct outreach to R&D heads at specialized CNS biotech firms like Neumora and Cerevel. Scientific Publications Publishing validation data in peer-reviewed journals to establish the assay as the industry standard for location-bias. Industry Conferences Presenting at neuropsychiatry and drug discovery symposiums to attract pharmaceutical pipeline managers. 3 CNS-Focused Biotech Companies like Neumora and Cerevel developing next-generation antidepressants and anxiolytics. Large-Scale CROs Entities like Eurofins and Evotec that can white-label or integrate the assay into their existing service catalogs. Government Research Institutes Organizations like NIDA investigating the therapeutic potential of psychedelics for public health. 3 Laboratory Overhead High costs associated with maintaining sterile cell cultures and high-resolution imaging/detection equipment. Specialized Consumables Ongoing expense for high-purity antibodies and chemical probes required for subcellular localization. Expert Personnel Competitive salaries for specialized pharmacologists and assay developers. 3 Per-Compound Screening Fee A transactional fee for testing individual compounds or small batches for location-bias. Library Screening Contracts Large-scale fixed-price contracts for screening entire chemical libraries (thousands of compounds). Consulting Retainers Ongoing advisory fees for guiding the medicinal chemistry strategy based on assay results. The idea has clearly defined B2B customers (CROs and Pharma) and a specific value proposition, making it ideal for mapping the value capture mechanism. · Generated 2026-08-02 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated